Fibrosis, also known as fibrotic scarring, is a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodeling and the formation of permanent scar tissue. If highly progressive, the fibrotic process eventually leads to organ malfunction and death. Fibrosis affects nearly every tissue in the body, such as lung, liver, kidney, bone marrow, etc. Fibrosis is the final, common pathological outcome of many chronic inflammatory diseases, including scleroderma, rheumatoid arthritis, Crohn’s disease, ulcerative colitis, myelofibrosis and systemic lupus erythematosus.

TargetMol’s Anti-Fibrosis Compound Library collects 1180 potential anti-fibrosis compounds, including inhibitors to TGF-beta, TNF-alpha, MMP, etc., antioxidants, anti-inflammatory compounds, etc. It is a powerful tool for research in fibrosis and related drug development.